APLS
NASDAQ · Biotechnology
Apellis Pharmaceuticals Inc
$41.03
+0.02 (+0.05%)
Financial Highlights (FY 2026)
Revenue
1.02B
Net Income
22.72M
Gross Margin
89.8%
Profit Margin
2.2%
Rev Growth
+137.0%
D/E Ratio
1.23
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 89.8% | 32.7% | 32.7% | 32.7% |
| Operating Margin | 5.5% | 3.7% | 3.7% | 3.1% |
| Profit Margin | 2.2% | 3.1% | 2.9% | 2.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.02B | 3.03B | 2.81B | 3.40B |
| Gross Profit | 914.91M | 991.28M | 918.85M | 1.11B |
| Operating Income | 56.23M | 112.10M | 104.61M | 105.27M |
| Net Income | 22.72M | 93.04M | 81.85M | 92.75M |
| Gross Margin | 89.8% | 32.7% | 32.7% | 32.7% |
| Operating Margin | 5.5% | 3.7% | 3.7% | 3.1% |
| Profit Margin | 2.2% | 3.1% | 2.9% | 2.7% |
| Rev Growth | +137.0% | +21.3% | +20.6% | +22.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.45B | 1.16B | 884.37M | 986.26M |
| Total Equity | 1.18B | 2.04B | 1.97B | 2.09B |
| D/E Ratio | 1.23 | 0.57 | 0.45 | 0.47 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 57.70M | 115.17M | 115.66M | 126.47M |
| Free Cash Flow | — | 42.87M | 48.47M | 53.10M |